Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women
Objectives: To investigate the efficacy and tolerability of the oral hormone replacement therapy (HRT) containing 1 mg estradiol (E2) plus 2 mg drospirenone (DRSP) in Thai women with postmenopausal symptoms. Material and Method: Fifty-five Thai women with postmenopausal symptoms participated in this...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80053059560&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50186 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
id |
th-cmuir.6653943832-50186 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-501862018-09-04T04:26:10Z Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women Sukanya Chaikittisilpa Surasak Angsuwathana Somsak Chaovisitsaree Mayuree Jirapinyo Kittisak Wilawan Krasean Panyakhamlerd Unnop Jaisamrarn Kitirat Techatraisak Nuntana Morakote Charnchai Suchartwatnachai Worapong Kongmephol Nimit Taechakraichana Medicine Objectives: To investigate the efficacy and tolerability of the oral hormone replacement therapy (HRT) containing 1 mg estradiol (E2) plus 2 mg drospirenone (DRSP) in Thai women with postmenopausal symptoms. Material and Method: Fifty-five Thai women with postmenopausal symptoms participated in this multicenter, open-label, non-comparative Phase IV study. The primary endpoint was the reduction of hot flushes after 12 weeks of treatment. Secondary endpoints included changes in frequency and intensity of menopausal symptoms as well as safety assessments after 4, 8, and 12 weeks of treatment. Results: Treatment with 1 mg E2 plus 2 mg DRSP reduced the frequency of hot flushes in 94.6% of women at the end of the 12-week treatment period. In 60% of women, the frequency of hot flushes was reduced to 10% or less, compared to baseline findings and 49.1% of women had no remaining hot flushes. Other postmenopausal symptoms such as vaginal dryness, urinary incontinence, dysuria, and dyspareunia improved. The most common adverse events were vaginal bleeding or spotting and breast tenderness. Conclusion: The oral HRT of 1 mg E2 plus 2 mg DRSP was effective and well tolerated by Thai women suffering from postmenopausal symptoms. 2018-09-04T04:26:10Z 2018-09-04T04:26:10Z 2011-09-01 Journal 01252208 2-s2.0-80053059560 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80053059560&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50186 |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
topic |
Medicine |
spellingShingle |
Medicine Sukanya Chaikittisilpa Surasak Angsuwathana Somsak Chaovisitsaree Mayuree Jirapinyo Kittisak Wilawan Krasean Panyakhamlerd Unnop Jaisamrarn Kitirat Techatraisak Nuntana Morakote Charnchai Suchartwatnachai Worapong Kongmephol Nimit Taechakraichana Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women |
description |
Objectives: To investigate the efficacy and tolerability of the oral hormone replacement therapy (HRT) containing 1 mg estradiol (E2) plus 2 mg drospirenone (DRSP) in Thai women with postmenopausal symptoms. Material and Method: Fifty-five Thai women with postmenopausal symptoms participated in this multicenter, open-label, non-comparative Phase IV study. The primary endpoint was the reduction of hot flushes after 12 weeks of treatment. Secondary endpoints included changes in frequency and intensity of menopausal symptoms as well as safety assessments after 4, 8, and 12 weeks of treatment. Results: Treatment with 1 mg E2 plus 2 mg DRSP reduced the frequency of hot flushes in 94.6% of women at the end of the 12-week treatment period. In 60% of women, the frequency of hot flushes was reduced to 10% or less, compared to baseline findings and 49.1% of women had no remaining hot flushes. Other postmenopausal symptoms such as vaginal dryness, urinary incontinence, dysuria, and dyspareunia improved. The most common adverse events were vaginal bleeding or spotting and breast tenderness. Conclusion: The oral HRT of 1 mg E2 plus 2 mg DRSP was effective and well tolerated by Thai women suffering from postmenopausal symptoms. |
format |
Journal |
author |
Sukanya Chaikittisilpa Surasak Angsuwathana Somsak Chaovisitsaree Mayuree Jirapinyo Kittisak Wilawan Krasean Panyakhamlerd Unnop Jaisamrarn Kitirat Techatraisak Nuntana Morakote Charnchai Suchartwatnachai Worapong Kongmephol Nimit Taechakraichana |
author_facet |
Sukanya Chaikittisilpa Surasak Angsuwathana Somsak Chaovisitsaree Mayuree Jirapinyo Kittisak Wilawan Krasean Panyakhamlerd Unnop Jaisamrarn Kitirat Techatraisak Nuntana Morakote Charnchai Suchartwatnachai Worapong Kongmephol Nimit Taechakraichana |
author_sort |
Sukanya Chaikittisilpa |
title |
Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women |
title_short |
Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women |
title_full |
Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women |
title_fullStr |
Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women |
title_full_unstemmed |
Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women |
title_sort |
clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal thai women |
publishDate |
2018 |
url |
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80053059560&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50186 |
_version_ |
1681423544490131456 |